Rachel Humphrey
Director/Board Member at PYXIS ONCOLOGY, INC.
Net worth: 249 675 $ as of 30/04/2024
Profile
Rachel W.
Humphrey is currently the President & Chief Executive Officer at Normunity, Inc. She is also an Independent Director at Pyxis Oncology, Inc., a Director at Asylia Therapeutics, Inc., and a Director at Sporos Bioventures, Inc. Her former positions include being an Independent Director at Xilio Therapeutics, Inc., Director & Chief Medical Officer at Treadwell Therapeutics, Inc., Vice President-Product Development at Bristol Myers Squibb Co., Head-Immuno Oncology at Eli Lilly & Co., Chief Medical Officer & Executive Vice President at Mirati Therapeutics, Inc., Senior Vice President at CytomX Therapeutics Holdings LLC, Senior Vice President & Head-Immuno Oncology at AstraZeneca LP, and Chief Medical Officer & Senior Vice President at CytomX Therapeutics, Inc. She was also the Chief Medical Officer at Black Diamond Therapeutics, Inc. and Head-Research & Development at Tio Bioventures.
Dr. Humphrey has also served as a Scientific Advisor at eFFECTOR Therapeutics, Inc. She received her undergraduate degree from Harvard University and her doctorate from Case Western Reserve University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC.
0.10% | 18/04/2024 | 58,064 ( 0.10% ) | 249 675 $ | 30/04/2024 |
Rachel Humphrey active positions
| Companies | Position | Start |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Director/Board Member | 11/08/2022 |
Normunity, Inc.
 Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | Chief Executive Officer | - |
Sporos Bioventures, Inc.
 Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Director/Board Member | 04/01/2022 |
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Director/Board Member | - |
Former positions of Rachel Humphrey
| Companies | Position | End |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Director/Board Member | 03/02/2022 |
| BLACK DIAMOND THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 04/08/2021 |
Tio Bioventures
 Tio Bioventures Investment ManagersFinance Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York. | Chief Tech/Sci/R&D Officer | 01/05/2020 |
Treadwell Therapeutics, Inc.
 Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 01/05/2020 |
| CYTOMX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 19/08/2019 |
Training of Rachel Humphrey
| Harvard University | Undergraduate Degree |
| Case Western Reserve University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 7 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA. | Health Technology |
AstraZeneca LP
 AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE. | Health Technology |
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Treadwell Therapeutics, Inc. operates as a clinical-stage oncology firm. It develops small molecules designed to leverage world-class, innovative science in cancer biology and immune-oncology with pan-cancer potential, including hematological malignancies from the TIO Discovery development engine. The company was founded by Tak Wah Mak and Mark R. Bray in July 2019 and is headquartered in New York, NY. | Health Technology |
Tio Bioventures
Tio Bioventures Investment ManagersFinance Tio Bioventures (Tio Bioventures) is a venture capital firm founded in 2019 by Tak Wah Mak and Shane Burgess. The firm is headquartered in New York. | Finance |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Health Technology |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Health Services |
Normunity, Inc.
Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Normunity, Inc. is a biotechnology company that creates precision immuno-oncology medicines called immune normalizers. The company is based in West Haven, CT and has subsidiaries in the United States. These medicines target novel mechanisms that free the body's normal immunity against cancer. Normunity is based on an ongoing academic-biotech partnership with the lab of Dr. Lieping Chen at Yale School of Medicine. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. The CEO of the company is Rachel W. Humphrey. | Commercial Services |
- Stock Market
- Insiders
- Rachel Humphrey
